At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 42 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled, Crossover Study to Investigate the Effect of Once-Weekly Tirzepatide on the Counter-Regulatory Response to Hypoglycemia in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating Tirzepatide and Placebo for Diabetes Mellitus, Type 2 and Hypoglycemia. Completed, enrolled 42 participants across 1 site.
Detailed Summary
The main purpose of this study is to learn more about how tirzepatide affects the body's response to low blood sugar (hypoglycemia). The study is open to participants with type 2 diabetes. It will last about 42 weeks for each participant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2, Hypoglycemia
CountriesAustria
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartFeb 2020
Primary CompletionJan 2022
TodayJul 2026
First PostedAug 8, 2019
Enrollment StartFeb 24, 2020
Primary CompletionJan 25, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.9 years ago
Interventions
Tirzepatidedrug
Administered SC
Placebodrug
Administered SC